Subscribe to RSS
DOI: 10.1055/s-0041-1730368
Proteinemia as a Prognostic Factor in Colorectal Cancers beyond Surgery and Chemotherapy
Abstract
Background Globally, 1,096,601, 704,376, and 48,541 new colon, rectum, and anus cancer cases were recorded in 2018, respectively. Besides, 551,269, 310,394 and 19,129 cases of colon, rectum, and anus cancer deaths occurred in the same year. As a result, these cancers ranked in the third level of cancer incidence, and in the second level of cancer mortality. As it is known, all cancer patients are subjected to cancer-induced and therapy-induced nutritional deficiencies (mainly of proteins and calories). The present study aimed to assess proteins level in colorectal cancer (CRC) patients who underwent surgery and chemotherapy.
Methods A combined retrospective and prospective study was performed. The present study enrolled 100 CRC patients with their data on surgical procedures and chemotherapy management. Assessments of the studied samples were conducted as a baseline before receiving chemotherapy and preoperatively as P0, while the period after that was termed as P1. The serum samples were collected to measure protein concentration. Total Protein Kit, Micro was used.
Results The mean age of the patients was 50.7 ± 12.88 years old. Only 8% had a positive CRC family history. Rectosigmoid cancer represented the most frequent site, figured in 41% of the cases, followed by rectum cancer. Multiple sites of CRC metastasis were recorded in 15% of the patients. All patients received chemoradiation. Folinic acid (leucovorin), 5-FU, and oxaliplatin (FOLFOX) was the most used regimen, administered in 40% of the patients. Oxaliplatin and capecitabine (also called Xeloda) (XELOX) were administered in 14% of the patients. Folinic acid (leucovorin), 5-FU, oxaliplatin, and irinotecan (FOLFOXIRI) were administered in 16% of the patients. Single-agent oxaliplatin or carboplatin were administered in 6% of the patients, each. 5-FU plus leucovorin was administered to12% of the patients. Three patients received irinotecan, and oxaliplatin (IROX). One patient received folinic acid (leucovorin), 5-FU and irinotecan (FOLFIRI). Also, Gemzar was administered to two patients only. A total of 80% of the patients underwent several surgical procedures. Anterior perineal resection (APR) and total mesorectal excision (TME) were the most common two surgeries, performed in 20 and in 30% of the patients, respectively. In P0 status, 44% of the patients suffered from low protein levels, and 13% of the patients were within the normal level. These findings were statistically different (p = 0.03). After CRC management (i.e., P1 status), 70% of the patients had protein deficiency. These results have strong significant differences (p = 0.000). The mean of protein concentration declined gradually after management, from 8.82 ± 0.9 μg/L to 6.21 ± 0.78 μg/L, with a strong association between a reduction in proteins levels towards deficiency and surgical procedures and chemotherapy protocols (p = 0.000).
Conclusion The incidence of CRC is increasing annually, and the chance of being diagnosed with this type of cancer has risen in recent years. In the present study, the male to female ratio was 1:1.5, and the 5th decade of life was the most common age for the diagnosis of CRC. A negative family history and bowel inflammatory diseases (IBD) history did not exclude people from exposure to the incidence of CRC. Colorectal cancer with localized and moderately differentiated adenocarcinoma were the most common types in the present work. Tumor distance from the anal verge seems to be very important and plays a significant role in the choosing of surgical intervention types and chemoradiation protocols. Colorectal cancer acts as a complex condition and, in addition to its management, nutritional state influences it in different mechanisms. Most patients suffered from hypoproteinemia after surgery and chemoradiation. As a result, alteration in the treatment outcomes, delaying in wound healing, and an increase in postoperative complications may occur.
Ethical Approval
The present study followed the Declaration of Helsinki and was approved by the local ethics committee of the center. Informed written consent was obtained from all patients.
Publication History
Received: 09 January 2021
Accepted: 22 March 2021
Article published online:
19 July 2021
© 2021. Sociedade Brasileira de Coloproctologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 11/2018; 68 (06) 394-424 DOI: 10.3322/caac.21492. . Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313. PMID: 30207593
- 2 Alrubai, Alaa Mobder Mohammed, Al-Naqqash, Manwar Abdulelah, & Alshewered, Ahmed Salih. 2020; Epidemiological and prognostic single center study of anal carcinoma. Journal of Coloproctology (Rio de Janeiro) 40 (03) 202-208 . Epub August 14, 2020. https://doi.org/10.1016/j.jcol.2020.01.003
- 3 Alrubai, Alaa Mobder Mohammed, Al-Naqqash, Manwar Abdulelah, & Alshewered, Ahmed Salih. 2020; Epidemiological and prognostic single center study of anal carcinoma. Journal of Coloproctology (Rio de Janeiro) 40 (03) 202-208 . Epub August 14, 2020. https://doi.org/10.1016/j.jcol.2020.01.003
- 4 Alhilfi, Haider Saadoon Qasim, Almohammadawi, Khalid Obiad Mohsin, Alsaad, Rasha Khalil Abduljalil, Ameen, Nyaz Ahmed, Aliedani, Basima Kadhim Abbood, Aldubaisi, Husam Jihad Imran, & Alshewered, Ahmed Salih Hussien. 2019; Colorectal cancer epidemiology and clinical study in Misan. Journal of Coloproctology (Rio de Janeiro) 39 (02) 159-162 . Epub June 13, 2019. https://doi.org/10.1016/j.jcol.2018.12.001
- 5 Iraqi Cancer Registry. Ministry Of Health, Iraqi Cancer Board, Baghdad, Iraq. 2011 https://moh.gov.iq/upload/upfile/ar/273.pdf
- 6 Iraqi Cancer Registry, Annual Report. Iraqi Cancer Registry Board, Ministry Of Health and Environment. Baghdad, Iraq: 2015
- 7 Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin 05/2020; 70 (03) 145-164 DOI: 10.3322/caac.21601. . Epub 2020 Mar 5. PMID: 32133645
- 8 Ravasco P. Nutrition in Cancer Patients. J Clin Med. 14.08.2019; 8 (08) 1211 DOI: 10.3390/jcm8081211. . PMID: 31416154; PMCID: PMC6723589
- 9 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR). Continuous Update Project Report: Diet, Nutrition, Physical Activity and Colorectal Cancer 2016. Revised 2018. London: World Cancer Research Fund International; 2018. aicr.org/continuous-update-project/reports/colorectal-cancer-2017-report.pdf
- 10 Gangadharan A, Choi SE, Hassan A. et al. Protein calorie malnutrition, nutritional intervention and personalized cancer care. Oncotarget 2017; 8 (14) 24009-24030
- 11 NCCN. 2020 Clinical Practice Guidelines in Oncology. Colon, Rectal, and Anal Cancers Version.2. www.nccn.org
- 12 Alberts SR, Grothy A. In: Casciato DA and Territo MC (editors). Manual of Clinical Oncology: Colorectal cancer. 7th edt.. Lippincott Williams & Wilkins; a Wolters Kluwer business. USA: 2012: 239-258
- 13 https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Bulletin/tp0100bul.pdf
- 14 Radhi AA, Muslim OT, Abdlmaged MA. Epidemiological distribution of colorectal cancer in AL-Diwaniyah province, Iraq: an observational study. J Pharm Sci & Res. 2018; 10 (07) 1758-1760 available at https://www.jpsr.pharmainfo.in/Documents/Volumes/vol10Issue07/jpsr10071831.pdf
- 15 Alsafi RAR, Metib NJ, Hameedi AD. et al. The Clinical and Pathological Characteristics of Colorectal Cancer in Young Age Group in Karbala Province/Iraq. Karbala J Med. 2018; 11 (02) 4025-4031 . available at https://journals.uokerbala.edu.iq/index.php/kj/article/view/372
- 16 Khalil KH, Al-Hassawi BA, Abdo JM. Histopathological evaluation of colorectal carcinoma. Duhok Medical Journal 2018; 12 (02) 45-68 . available at https://www.iasj.net/iasj/article/162945
- 17 Palta M, Willett CG, Czito BG. Principles and practice of radiation oncology: Cancer of the Colon and Rectum. In: Halperin EC, Perez CA, Brady LW. et al., (editors) 6th ed.. Philadelphia: Lippincott Williams & Wilkins; 2013: 1215-1230
- 18 Al Dahhan SA, Al Lami FH. Epidemiology of Colorectal Cancer in Iraq, 2002-2014. Gulf J Oncolog 2018 Jan01(26):23–26. PMID: 29607818
- 19 https://www.nice.org.uk/ The National Institute for Health and Care Excellence/guidance/cg131/ colorectal cancer diagnosis and management/. 2014
- 20 http://publications.iarc.fr/ The International Agency for Research on Cancer/Non-Series-Publications/World cancer report/. 2014
- 21 http://www.who.int/cancer/colorectal/en/2014
- 22 Dilly RS, Barretta C, Matos CH. et al. Nutritional status and consumption of inflammatory and anti-inflammatory foods by patients with inflammatory bowel diseases. J Coloproctol (Rio J) 2020; 40 (02) 99-104 . Available at https://www.scielo.br/pdf/jcol/v40n2/2237-9363-jcol-40-02-0099.pdf
- 23 Giovannucci E, Wu K. Cancer Epidemiology and Prevention: cancer of the colon and rectum. In: Schottenfeld D, Fraumeni JF. 3rd Edition. Oxford University Press, Inc.; USA: 2006: 809-830
- 24 Khalid OMA, Haider SQA, Ahmed SHA. Epidemiological data of 1418 Cancer Cases of Inpatient in Al-Sadder Teaching Hospital, Misan Province from 2011-2018 (Surveillance Study). Med Sci 2018; 22 (93) 455-461 . Available at https://www.researchgate.net/publication/326775771_Epidemiological_data_of_1418_Cancer_Cases_of_Inpatient_in_Al-Sadder_Teaching_Hospital_Misan_Province_from_2011-2018_Surveillance_Study
- 25 www.seer.cancer.gov/statfacts/html/anus.html
- 26 Franklin RA, Giri S, Valasareddy P, Lands LT, Martin MG. Comparative Survival of Patients With Anal Adenocarcinoma, Squamous Cell Carcinoma of the Anus, and Rectal Adenocarcinoma. Clin Colorectal Cancer 03/2016; 15 (01) 47-53 DOI: 10.1016/j.clcc.2015.07.007. . Epub 2015 Aug 1. PMID: 26362848.
- 27 Khan MAS, Ang CW, Hakeem AR, Scott N, Saunders RN, Botterill I. The Impact of Tumour Distance From the Anal Verge on Clinical Management and Outcomes in Patients Having a Curative Resection for Rectal Cancer. J Gastrointest Surg. 12/2017; 21 (12) 2056-2065 DOI: 10.1007/s11605-017-3581-0. . Epub 2017 Sep 18. PMID: 28924962
- 28 Mohiuddin M, Willett CG. In: Halperin EC, Perez CA, Brady LW. et al., (editors) Principles and practice of radiation oncology: Colon and Rectum. 6th ed.. Philadelphia: Lippincott Williams & Wilkins; 2015: 1366-1382
- 29 Bosset JF, Calais G, Mineur L. et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in colorectal cancer: Long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014; 15: 184-190
- 30 Sauer R, Liersch T, Merkel S. et al. Preoperative versus postoperative chemoradiotherapy for locally advanced colorectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926-1933
- 31 Quirke P, Steele R, Monson J. et al. Effect of the plane of surgery achieved on local recurrence in patients with operable colorectal cancer: A prospective study using data from the MRC CR07 and NCIC-CTG Co16 randomised clinical trial. Lancet 2009; 373: 821-828
- 32 Bosset JF, Collette L, Bardet E. et al. Chemotherapy with preoperative radiotherapy in colorectal cancer. N Engl J Med 2006; 355: 1114-1123
- 33 Smalley SR, Benedetti JK, Williamson SK. et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant colorectal cancer: GI INT 0144. J Clin Oncol 2006; 24: 3542-3547
- 34 Gunderson LL, Sargent D, Tepper JE. et al. Impact of T and N stage and treatment on survival and relapse in adjuvant colorectal cancer: A pooled analysis. J Clin Oncol 2004; 22: 1785-1796
- 35 Mattox TW. Cancer Cachexia: Cause, Diagnosis, and Treatment. Nutr Clin Pract 2017; 32: 599-606
- 36 Ravasco P, Grillo IM, Vidal P. et al. Nutritional Deterioration in Cancer: The Role of Disease and Diet. Clin Oncol 2003; 15: 443-450
- 37 Mantzorou M, Koutelidakis A, Theocharis S. et al. Clinical Value of Nutritional Status in Cancer: What is its Impact and how it A_ects Disease Progression and Prognosis?. Nutr Cancer 2017; 69: 1-26
- 38 Weimann A, Braga M, Carli F. et al. ESPEN guideline: Clinical nutrition in surgery. Clin Nutr 2017; 36: 623-650
- 39 Blauwho-Buskermolen S, Versteeg KS, De Van Der Schueren MA. et al. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients with Metastatic Colorectal Cancer. J Clin Oncol 2016; 34: 1339-1344
- 40 Ravasco P, Monteiro Grillo I, Marques Vidal P. et al. Dietary conseling improves patient outcomes: A prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 2005; 23: 1431-1438
- 41 Lieffers JR, Bathe OF, Fassbender K. et al. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer 2012; 107: 931-936
- 42 Deutz NE, Safar A, Schutzler S. et al. Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr 2011; 30: 759-768
- 43 Omlin A, Blum D, Wierecky J. et al. Nutrition impact symptoms in advanced cancer patients: Frequency and specific interventions, a case–control study. J Cachexia Sarcopenia Muscle 2013; 4: 55-61
- 44 Van Blarigan EL, Fuchs CS, Niedzwiecki D. et al. Association of Survival with Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis: The CALGB 89803/Alliance Trial. JAMA Oncol 2018; 4: 783-790